Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients.

@article{Pasini2008NebivololTR,
  title={Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients.},
  author={Anna Maria Fratta Pasini and Ulisse Garbin and Chiara Stranieri and Veronica Boccioletti and Chiara Mozzini and Stefania Manfro and Andrea Pasini and Mattia Cominacini and Luciano Cominacini},
  journal={American journal of hypertension},
  year={2008},
  volume={21 11},
  pages={1251-7}
}
BACKGROUND This study was conducted to evaluate (i) the effect of nebivolol, a selective beta1-adrenergic receptor antagonist, on plasma concentration of asymmetric dimethylarginine (ADMA) and on flow-mediated dilation (FMD) in essential hypertensive patients; (ii) the effect of serum derived from the treated hypertensive patients on ADMA and on dimethylarginine dimethylaminohydrolase 2 (DDAH2), the enzyme that selectively degrades ADMA, in human umbilical vein endothelial cells (HUVECs… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Similar Papers

Loading similar papers…